Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for JMIA, HRTX and TUSK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Monday, 17 June 2019 09:10 PM

Levi & Korsinsky, LLP

Topic:
5

NEW YORK, NY / ACCESSWIRE / June 17, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

Jumia Technologies AG (NYSE: JMIA)

Class Period: Purchasers of American Depositary Shares between April 12, 2019 and May 9, 2019
Lead Plaintiff Deadline : July 15, 2019
Join the action: https://www.zlk.com/pslra-1/jumia-technologies-ag-loss-form?prid=1976&wire=1

Allegations: Jumia Technologies AG made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (a) Jumia had materially overstated its active customers and active merchants; (b) Jumia's representations about its orders, order cancellations, undelivered orders and returned orders lacked a sufficient factual basis and materially overstated the Company's sales; (c) Jumia failed to sufficiently disclose related party transactions; and (d) Jumia's financial statements were presented in violation of applicable accounting standards.

To learn more about the Jumia Technologies AG class action contact [email protected].

Heron Therapeutics, Inc. (NASDAQ: HRTX)

Class Period: October 31, 2018 - April 30, 2019
Lead Plaintiff Deadline : August 5, 2019
Join the action: https://www.zlk.com/pslra-1/heron-therapeutics-inc-loss-form?prid=1976&wire=1

Allegations: Heron Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls ("CMC") and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron's NDA for HTX-011; and (iii) as a result, Heron's public statements were materially false and misleading at all relevant times.

To learn more about the Heron Therapeutics, Inc. class action contact [email protected].

Mammoth Energy Services, Inc. (NASDAQ: TUSK)

Class Period: October 19, 2017 - June 5, 2019
Lead Plaintiff Deadline : August 6, 2019
Join the action: https://www.zlk.com/pslra-1/mammoth-energy-services-inc-loss-form?prid=1976&wire=1

Allegations: Mammoth Energy Services, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Mammoth's subsidiary, Cobra, improperly obtained two infrastructure contracts with PREPA that totaled over $1.8 billion; (2) specifically, the contracts were awarded as the result of improper steering and not a competitive RFP process; and (3) as a result, Defendants' statements about Mammoth's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the Mammoth Energy Services, Inc. class action contact [email protected].

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
5
Back to newsroom
Back to Newsroom
Share by: